surmount-1 tirzepatide 15 mg weight loss percent Treatment Leads to of up to 22.5% in Clinical Trial Tirzepatide: Breakthrough in Obesity and

J GEN INTERN MED 41 , 807818 (2026)

Pharmaceutical companies are already racing to develop: next-generation GLP-1 drugs oral GLP-1 formulations dual- and triple-agonist metabolic therapies combination treatments targeting obesity and metabolic syndrome For sponsors, the commercial stakes are enormous

The first change most researchers notice is the return of appetite

If side effects are severe, some patients work with their providers to use every-other-week dosing as a temporary step while titrating up, allowing their digestive system to adjust gradually

Although Wegovy can be highly effective, certain groups should not use this weight-loss medication: Pregnant or breastfeeding individuals: The drug may pass through breast milk and could affect the baby

Tirzepatide as Compared with Semaglutide for the Treatment of Type 2 Diabetes